Axiron Sales Still Robust and Tracking Above Expectations; Launch of Generics Just a Matter of Time
We maintain our AUD 0.40 per share fair value estimate for no-moat-rated Acrux following the release of better-than-expected quarterly net sales of Axiron by licensee partner Eli Lilly. Sales for the three months to Dec. 31, 2016 totaled USD 39.9 million, down 4% on the previous corresponding period but up 2% on a sequential quarterly basis. Sales are now tracking ahead of our forecast USD 82 million for the full year, fiscal 2017, and suggest underlying demand for the product remains strong.Su...
Acrux is a pharmaceutical company engaged in the development and commercialization of specialty and generic transdermal and topical pharmaceuticals for global markets. Co.'s topical or transdermal pharmaceutical product portfolio can be segregated into two streams - generic pharmaceutical products and specialty pharmaceutical products.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.